Evidence map›Paper›PMID 39037688›Full record

ArticleJournal of neuro-oncology2024

Effect of Jardiance on glucose uptake into astrocytomas.

Chiara Ghezzi, Benjamin M Ellingson, Albert Lai, Jie Liu, Jorge R Barrio, Ernest M Wright

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuro-oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chiara GhezziDepartment of Physiology, The David Geffen School of Medicine at UCLA, Los Angeles, CA, 90095-1751, USA.
Benjamin M EllingsonDepartment of Radiological Sciences, The David Geffen School of Medicine at UCLA, Los Angeles, CA, 90095, USA.
Albert LaiDepartment of Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, CA, 90095, USA.
Jie LiuDepartment of Molecular and Medical Pharmacology, The David Geffen School of Medicine at UCLA, Los Angeles, CA, 90095, USA.
Jorge R BarrioDepartment of Molecular and Medical Pharmacology, The David Geffen School of Medicine at UCLA, Los Angeles, CA, 90095, USA.
Ernest M WrightDepartment of Physiology, The David Geffen School of Medicine at UCLA, Los Angeles, CA, 90095-1751, USA. ewright@mednet.ucla.edu.ORCID http://orcid.org/0000-0002-1023-4391

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
Role of decorin and diffusion MRI in anti-VEGF efficacy for recurrent glioblastomaR01CA270027 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TIMOTHY CLOUGHESY, Benjamin M. Ellingson · 2022 to 2026
$3.0M
Quantitative molecular MR-PET imaging of glycolysis in glioblastomaR01CA279984 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Benjamin M. Ellingson, David A. Nathanson · 2023 to 2026
$2.4M
Metabolic MRI for quantifying aerobic glycolysis and immune function in gliomasR21CA223757 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ELLINGSON, BENJAMIN M. · 2018 to 2019
$366k
NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA270027NCI NIH HHS R01 CA279984NCI NIH HHS R21 CA223757NIH HHS R01CA270027U.S. Department of Defense CA220732
6 · The paper itself

Abstract

purposeSGLT2, the sodium glucose cotransporter two, is expressed in human pancreatic, prostate and brain tumors, and in a mouse cancer model SGLT2 inhibitors reduce tumor glucose uptake and growth. In this study we have measured the effect of a specific SGLT2 inhibitor, Jardiance® (Empagliflozin), on glucose uptake into astrocytomas in patients.

methodsWe have used a specific SGLT glucose tracer, α-methyl-4-[

resultsIn all five patients an oral dose (25 or 100 mg) of Jardiance reduced Me4FDG tumor accumulation, highly significant inhibition in four, and inhibited SGLT2 activity in the kidney.

conclusionsThese initial experiments show that SGLT2 is a functional glucose transporter in astocytomas, and Jardiance inhibited glucose uptake, a drug approved by the FDA to treat type 2 diabetes mellitus (T2DM), heart failure, and renal failure. We suggest that clinical trials be initiated to determine whether Jardiance reduces astrocytoma growth in patients.

Indexed as

AstrocytomaBrain NeoplasmsGlucosePositron-Emission TomographySodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsAgedFemaleFluorodeoxyglucose F18GlucosidesHumansMaleMiddle AgedFluorodeoxyglucose F18GlucoseGlucosidesSLC5A2 protein, humanSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsGlioblastomaMe4FDGPETSGLT2SGLT2i

Identifiers

PMID39037688
PMCPMC11341586

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.